Key result
On-label TAVR for aortic regurgitation yields ~97% technical success and less migration versus off-label devices.
Why the study?
Evidence comparing clinical outcomes of different new-generation TAVR devices in patients with aortic regurgitation at high surgical risk remains limited.
Do on-label TAVR devices improve clinical and procedural outcomes compared to off-label self-expanding and balloon-expandable TAVR devices in patients with aortic regurgitation?
Meta-Analysis (n=2,682)
Yes
Do on-label TAVR devices improve clinical and procedural outcomes compared to off-label self-expanding and balloon-expandable TAVR devices in patients with aortic regurgitation?
In patients with aortic regurgitation, on-label TAVR devices provide superior procedural success and lower rates of valve migration and residual regurgitation compared to off-label devices, despite similar 1-year mortality.
No takes yet. Share an insight, caveat, or question.
Supports on-label TAVR preference in aortic regurgitation for better procedural success; extends evidence via meta-analysis of dedicated devices.
Peng et al. (2025) conducted a meta-analysis in aortic regurgitation (n=2,682). On-label TAVR devices vs. Off-label self-expanding and balloon-expandable TAVR devices was evaluated on 1-year all-cause mortality (95% CI 7.2% to 14.7%). On-label TAVR devices for aortic regurgitation yielded higher technical success (97%) and lower rates of valve migration (2%) compared to off-label devices, with similar 1-year mortality (10.4%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: